Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.
1. A compound of the following formula:
wherein X is F or Cl;
Y is NH, O, or S;
R is NH 2 , OH, SO 2 NH 2 , SO 2 N(CH 3 )H, SO 2 N(CH 3 ) 2 , or CONH 2 ;
m is an integer from 2 to 6; and
n is an integer from 1 to 2 in which a two-carbon fragment (n =2) includes
for Z═H or OH.
2. The compound of claim 1 , wherein X is F.
3. The compound of claim 1 , wherein Y is NH or O.
4. The compound of claim 1 , wherein m is 4, 5, or 6.
5. The compound of claim 1 , wherein n is 2.
6. The compound of claim 1 , wherein R is NH 2 , OH, SO 2 NH 2 , or SO 2 N(CH 3 ) 2 .
7. The compound of claim 1 , wherein:
X is F;
Y is NH;
R is NH 2 , OH, SO 2 NH 2 , SO 2 N(CH 3 ) 2 , or CONH 2 ;
m is 4 or 5; and
n is 0 or n is 2 when Z is OH.
8. A compound selected from the group consisting of:
Compound
Structure
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
.
9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically-acceptable carrier.
10. A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically-acceptable carrier.
11. The composition of claim 9 , wherein the pharmaceutically-acceptable carrier is selected from the group consisting of alcohols, polyol solvents, and aqueous solutions of mono- or disaccharides.
12. The composition of claim 9 further comprising a chemotherapeutic agent.
13. The composition of claim 12 , wherein the chemotherapeutic agent is selected from the group consisting of decarbazine, doxorubicin, daunorubicin, cyclophosphamide, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, gemcitabine, cisplatin, carboplatin, oxaliplatin, satraplatin, and chlorambucil.
14. The composition of claim 9 , further comprising a therapeutic agent blocking binding of TNFα to its receptor or subsequent signal transduction.
15. The composition of claim 14 , wherein the therapeutic agent is an anti-TNFα antibody or soluble TNFα receptor.
16. The composition of claim 9 , further comprising an agent selected from the group consisting of methotrexate, an anti-inflammatory corticosteroid, a nonsteroidal anti-inflammatory drug, and combinations thereof.
17. A method for the treatment of cancer in a patient in need thereof, wherein said cancer is prostate cancer, mastocytoma, melanoma, breast cancer, lung cancer, or pancreatic cancer, comprising administration to said patient of a therapeutically effective amount of a compound as defined in claim 1 .
18. A method for the treatment of an autoimmune disease in a patient in need thereof, wherein said autoimmune disease is rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, Systemic Lupus Erythematosus (SLE), eczema, gout, inflammatory bowel disease, or multiple sclerosis, comprising administration to said patient of a therapeutically effective amount of a compound as defined in claim 1 .
19. The method according to claim 18 , wherein the autoimmune disease is Crohn's disease, inflammatory bowel disease, or multiple sclerosis.